Clinical and pathologic predictors of survival in XXXX with @entity6732 .

@entity1 @entity704 @entity5 @entity1737 @entity6732 @entity299 @entity204
BACKGROUND: The aim of this study is to evaluate the impact of thymectomy in @entity1 with @entity6732 and to identify clinical and histopathological factors associated with improved long-term outcome of surgery. METHODS: We treated 74 @entity1 between February 1987 and July 1993. There were 29 total and 36 simple thymectomies. These last cases, all non-myasthenic, had @entity704 (n=30) but 6 had @entity704 . Nine @entity5 were no-resected (5 @entity704 ). Minimum follow-up by Department of Thoracic Surgery Istituto Nazionale Tumori was 60 months after thymectomy. We divided the specimens according to Marino and Muller-Hermelink's classification: 54 @entity704 , 18 @entity704 and 2 no-diagnosis specify @entity704 . There were 53 stage I, 1 stage II, 13 stage III, 5 stage IVa and 2 stage IVb according to Masaoka. RESULTS: Forty-six @entity1 with treated @entity704 were alive without disease at the end of follow-up, the remaining 8 died from recurrence in 6, a new @entity5 in 1 and a @entity299 in the last. Of 18 @entity704 9 were alive at the end of follow-up (1 with recurrence), only 4 dead from recurrence. The actuarial survival of @entity1 with @entity704 was 88.5% at 5 years, (73.6% in cortical type, 85.7% in medullary type, 93.9% in mixed type, 100% in predominantly cortical type). @entity1737 didn't influence the survival: 87.3 (no MG) vs 90%. Advanced stage @entity704 significantly increased the risk of @entity204 from early stage I: 32.4 vs 100% at 5 years. In @entity704 @entity1 with @entity704 ( @entity704 ) died less than others: the actuarial probability of survival at 5 years was 90 vs 68%. CONCLUSIONS: Thymectomy was the best treatment to long term outcome. In our experience, survival was related to histotype and to local extension of @entity5 .
